 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF has announced that an abstract covering the anti-depressant activity of its lead compound 2-bromo-LSD BETR-001 has been accepted for poster presentation at the FENS Forum to be held in Paris on July 9-13. The study, led by Vern Lewis, is part of BetterLifes collaboration with the laboratory of Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience. 